The US Senate backed legislation that would bar certain Chinese biotech companies from receiving federal funding and prohibit American investments in sensitive Chinese industries https://t.co/vojN60dgeE ...

A pundit at an influential U.S. bank is quite bullish on the company's future.An analyst's initiation of coverage was the spark that lit the fire underneath Scholar Rock's (SRRK 6.05%) equity on Thursday. The clinical-stage biotech's share price ballooned by 6% in response, on a trading day when the benchmark S&P 500 (^GSPC -0.28%) sagged by 0.3%. A rock of a stockWell before market open, Tazeen Ahmad of Bank of America Securities launched her tracking of Scholar Rock. The reason the market reacted so stron ...

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual 1x1 mee ...

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling more than 250 points on Thursday.The Dow traded down 0.60% to 46,320.74 while the NASDAQ fell 0.44% to 22,942.90. The S&P 500 also fell, dropping, 0.47% to 6,722.31.Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Materials Stocks Delivering High-Dividend YieldsLeading and Lagging SectorsConsumer staples shares jumped by 0.3% on Thursday.In trading on Wednesday, industrials stocks fell by 0.9%.Top Head ...

– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory patients; all three patients remained off immunomodulators since infusion and are off or tapering steroids as of the data cut-off – – CAR T cell expansion in all three patients without preconditioning was similar to expansion across 30+ patients dosed with preconditioning in the other RESET™ trials – – Initial dose data support continued exploration of rese-cel without ...

Key Takeaways Black Diamond hit a 52-week high of $4.1 on Oct. 8, soaring 86.4% year to date.Silevertinib showed durable responses and good tolerability in phase I EGFRm NSCLC data.BDTX focuses solely on silevertinib after outlicensing BDTX-4933 to Servier Pharmaceuticals.Black Diamond Therapeutics, Inc. (BDTX) performance has been outstanding in 2025. Shares of this clinical-stage oncology company hit a 52-week high of $4.1 on Oct. 8.Year to date, BDTX shares have skyrocketed 86.4% compared with the indust ...

U.S. stock futures were slightly lower this morning, with the Nasdaq futures falling around 0.1% on Thursday.Shares of Helen of Troy Ltd (NASDAQ:HELE) fell sharply in today's pre-market trading following second-quarter results.Helen Of Troy reported quarterly earnings of 59 cents per share which beat the analyst consensus estimate of 53 cents per share. The company reported quarterly sales of $431.781 million which beat the analyst consensus estimate of $418.806 millionHelen Of Troy said it sees FY2026 adju ...

SANTA ANA, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today issued the following statement in response to recent shareholder inquiries regarding its current trading status on the OTC Expert Market and the display of a $0.00 common stock, $0.0001 par value per share (the “Common Stock ...

The biggest news this week has been Zenas BioPharma, Inc.'s (NASDAQ: ZBIO ) licensing agreement with InnoCare ( OTCPK:INCPF ). It's a deal tipped to be worth $2 billion, with Zenas gaining rights to the global market, onlyI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an appreciati ...